How many drugs treat Chronic Non-Allergic Rhinitis?

Drug Landscape tracks 8 marketed treatments for Chronic Non-Allergic Rhinitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chronic-non-allergic-rhinitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chronic Non-Allergic Rhinitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic Non-Allergic Rhinitis (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic Non-Allergic Rhinitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Arnuity Ellipta	FLUTICASONE FUROATE	Haleon Us Holdings	Corticosteroid	Glucocorticoid receptor	2007-01-01
Flonase	fluticasone propionate	GSK (GlaxoSmithKline)	Inhaled/intranasal corticosteroid	Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor	1994-11-04
Pulmicort Respules	BUDESONIDE	AstraZeneca K.K.	Corticosteroid [EPC]	Glucocorticoid receptor	1994-01-01
Elocon	MOMETASONE FUROATE	Merck & Co.	Corticosteroid	Progesterone receptor	1987-01-01
Verdeso	DESONIDE	Padagis Us	Corticosteroid [EPC]	Glucocorticoid receptor	1972-01-01
Nasonex	Nasonex	University of Alberta		Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor
Flixotide	Flixotide	Mundipharma Research Limited		Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor
Fluticason	Fluticason	Creighton University		Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Chronic Non-Allergic Rhinitis
AstraZeneca K.K. · 1 drug in Chronic Non-Allergic Rhinitis
Creighton University · 1 drug in Chronic Non-Allergic Rhinitis
GSK (GlaxoSmithKline) · 1 drug in Chronic Non-Allergic Rhinitis
Haleon Us Holdings · 1 drug in Chronic Non-Allergic Rhinitis
Merck & Co. · 1 drug in Chronic Non-Allergic Rhinitis
Mundipharma Research Limited · 1 drug in Chronic Non-Allergic Rhinitis
Padagis Us · 1 drug in Chronic Non-Allergic Rhinitis
Teva Pharm · 1 drug in Chronic Non-Allergic Rhinitis
University of Alberta · 1 drug in Chronic Non-Allergic Rhinitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic Non-Allergic Rhinitis:

Cite this brief

Drug Landscape (2026). Chronic Non-Allergic Rhinitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-non-allergic-rhinitis. Accessed 2026-06-10.

Chronic Non-Allergic Rhinitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing